Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.55 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.52 |
| ▸ | ITK | Q08881 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21568852 | 0.87 | RAB9A (0.67) | GSK3BDYRK1ARAB9ANPC1MEN1 | |
| SCHEMBL4909124 | 0.83 | RAB9A (0.74) | GSK3BDYRK1ARAB9ANPC1MEN1 | |
| SCHEMBL21568046 | 0.81 | GSK3B (0.65) | GSK3BDYRK1ARAB9ANPC1MEN1 | |
| SCHEMBL21568128 | 0.81 | RAB9A (0.73) | GSK3BDYRK1ARAB9ANPC1MEN1 | |
| SCHEMBL21568343 | 0.80 | DYRK1A (0.59) | GSK3BDYRK1ARAB9ANPC1MEN1 | |
| SCHEMBL23256895 | 0.80 | DYRK1A (0.68) | GSK3BDYRK1ARAB9ANPC1MEN1 | |
| SCHEMBL23256870 | 0.80 | DYRK1A (0.70) | GSK3BDYRK1ARAB9ANPC1MEN1 | |
| SCHEMBL23256883 | 0.79 | DYRK1A (0.66) | GSK3BDYRK1ARAB9ANPC1MEN1 | |
| SCHEMBL21568073 | 0.78 | DYRK1A (0.62) | GSK3BDYRK1ARAB9ANPC1MEN1 | |
| SCHEMBL21568130 | 0.78 | DYRK1A (0.65) | GSK3BDYRK1ARAB9ANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | VHL, TP53, NUDT1 | GSK3B 4096/4885DYRK1A 4664/4885RAB9A 3882/4885 |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | VHL, TP53, NUDT1 | GSK3B 4200/4885DYRK1A 4618/4885RAB9A 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.